2015-10-01, Ilhan, MAHMUT MUZAFFER, Kahraman, Ozlem Timirci, Turan, Saime, Turgut, SEDA, Karaman, Ozcan, Zeybek, Umit, SHUKUROV, Samir, Yaylim, Ilhan, Tasan, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL

Objectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.

2018-07-01, Ilhan, Muzaffer, KARAMAN, ÖZCAN, Yasin, Ayse Irem, TURGUT, SEDA, TAŞAN, ERTUĞRUL, KARAMAN, ÖZCAN, YASİN, AYŞE İREM, TURGUT, SEDA, TAŞAN, ERTUĞRUL

Objective: Obesity is a chronic metabolic disorder that leads to the increased risk of cardiovascular diseases. This study aims to investigate the effect of weight loss on the platelet count and volume, which is associated with cardiovascular diseases. Methods: In total, 56 obese patients were recruited for the study. The parameters were retrospectively evaluated before and after 6 months of surgery. Results: The mean weight of the patients was 126.2±23.1 kg before surgery and 91.8±20.5 kg after surgery (p<0.001). The mean platelet counts were 292.5±58.6×10³/µL before surgery and 246.8±59.1×10³/µL after surgery (p<0.001). The mean platelet volumes were 10.4±1.0 fL and 11.6±0.9 fL before and after surgery, respectively (p<0.001). The mean platelet counts before surgery were correlated with the mean platelet volume, mean weight, and mean body mass index (p<0.01, r=−0.39, p<0.01, r=0.35, p<0.01, r=0.41, respectively). The mean platelet counts after surgery were correlated with the mean platelet volume (p<0.001, r=−0.68). Conclusion: This study demonstrated decreased platelet counts and increased platelet volume at 6 months after surgery in obese patients. Further long-term and prospective studies are warranted to clarify these results and pathopsychological mechanisms involved.

2021-03-01T00:00:00Z, Ilhan, Muzaffer, Turan, Saime, Turgut, Seda, Korkmaz, Gurbet, Ozkan, Nazli Ezgi, KARAMAN, Özcan, Yaylim, Ilhan, TAŞAN, ERTUĞRUL, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL

Objevtive: Acromegaly is a rare disease characterized by growth hormone hypersecretion generally arising from pituitary adenomas. Survivin, an apoptosis inhibitor protein, plays an important role in cell cycle regulation and possibly involves hypophysis gland proliferation mechanisms. However, the underlying causes of somatotroph adenomas with different behaviors and useful prognostic markers are still not fully understood. We investigated possible associations between survivin gene promoter -31 G\C genotypes and serum survivin level and clinical prognostic factors in acromegaly. Material and Methods: Sixty-eight acromegaly patients and 171 age-sex matched control subjects were enrolled in the study. Survivin -31 G\C polymorphism was performed by using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Blood GH and IGF1 levels were assayed using a chemiluminescence immunometric assay. Serum survivin levels were determined by ELISA. Results: Acromegaly patients had significantly higher serum survivin levels than controls (p=0.001). We found no significant association between acromegaly patients and controls in terms of survivin gene promoter -31 G\C genotype distribution and allele frequencies. No correlation was found between disease characteristics and survivin gene polymorphisms. Conclusion: Our study suggests that serum survivin levels might be associated with acromegaly, but survivin -31 G\C polymorphisms do not modify individual susceptibility to acromegaly in the Turkish population.

2018-01-30, ILHAN, MAHMUT MUZAFFER, Turgut, SEDA, TURAN, S, Demirci, Cekic, ERGEN, HA, Korkmaz, Dursun, MEZANI, B, KARAMAN, O, YAYLIM, I, APAK, MR, TASAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL

Oxidative status is attributed to endothelial dysfunction and might be one of the key mechanisms of endothelial dysfunction in acromegaly. In this study, we aimed to investigate the effect of acromegaly on superoxide dismutase (SOD) and total antioxidant capacity (TAC) levels, and the possible influence of human manganese superoxide dismutase (MnSOD) polymorphism on these levels. 51 acromegaly patients and 57 age and sex matched healthy subjects were recruited to the study in Bezmialem Vakif University Hospital between 2011 and 2014. The median SOD and TAC levels were 42.7 (33-60) pg/mL and 1,313.7 (155-1,902) μM in acromegaly; and 46.3 (38-95) pg/mL and 1,607.3 (195-1,981) μM in healthy subjects (p < 0.001, p < 0.001). SOD levels were decreased in controlled and uncontrolled patients compared to healthy subjects (p = 0.05 and p = 0.002, respectively). Controlled and uncontrolled acromegaly displayed significantly decreased levels of TAC compared to healthy subjects (p < 0.05 and p < 0.001, respectively). SOD levels were not associated with MnSOD polymorphisms in acromegaly. In conclusion, this study showed that acromegaly was associated with decreased levels of SOD and TAC, and controlling the disease activity could not adequately improve these levels.

2015-01-01, Ilhan, MAHMUT MUZAFFER, TOPTAS-HEKIMOGLU, Bahar, YAYLIM, Ilhan, Turgut, SEDA, TURAN, Saime, Karaman, Ozcan, Tasan, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL

Objective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge.We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly. Design, Patients, and Methods. 52 acromegaly patients (mean age 45.7 ± 1.9 years) and 83 controls (mean age 43.1 ± 2.6 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods. Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (𝑃 = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (𝑃 = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; 𝑃 = 0.020). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (𝑃 = 0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (𝑃 < 0.001). Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status.

2017-01-01, İLHAN, MAHMUT MUZAFFER, EKİNCİ, İSKENDER, KARAMAN, ÖZCAN, TURGUT, SEDA, TAŞAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TURGUT, SEDA, TAŞAN, ERTUĞRUL

2014-07-01, Ilhan, MAHMUT MUZAFFER, Arabaci, ELİF, Turgut, SEDA, Karaman, Ozcan, DANALIOGLU, Ahmet, Tasan, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, ARABACI, ELİF, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL

Purpose Gastrointestinal tract is one of the most affected systems in hypothyroidism. Despite decreased esophageal emptying, prolonged esophageal and gastric transit time have been indicated in previous reports, the mechanism of thyroid hormones activity and antibodies on the esophagus motility is not yet fully understood. This study was conducted to evaluate the esophagus motility by manometry in hypothyroid patients.

2016-03-01, Ilhan, MAHMUT MUZAFFER, Tiryakioglu, N. O., KARAMAN, O., Coskunpinar, E., YILDIZ, R. S., TURGUT, SEDA, Tiryakioglu, D., TOPRAK, HÜSEYİN, TASAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TURGUT, SEDA, TOPRAK, HÜSEYİN, TAŞAN, ERTUĞRUL

Purpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.

2017-05-01, Turgut, SEDA, Ilhan, Muzaffer, Turan, Saime, Karaman, Ozcan, Yaylim, Ilhan, Kucukhuseyin, Ozlem, Tasan, ERTUĞRUL, TURGUT, SEDA, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL

Aim: Prolactinomas are thought to arise from clonal expansion of a single mutated cell which is subjected to growth stimuli of several permissive factors, although the pathogenetic mechanisms underlying tumorigenesis remain unclear. The present study aimed to investigate the role of p16 (540C→G and 580C→T) and mouse double minute 2 (MDM2) (SNP309T→G) gene polymorphisms in tumorigenesis and characteristics of prolactinoma. Patients and methods: A total of 74 patients with prolactinoma and 100 age- and gender-matched healthy individuals were enrolled in the study. Serum prolactin levels were measured by enzyme-linked immunosorbent assay (ELISA). p16 and MDM2 polymorphisms were determined by polymerase chain reaction-restriction fragment polymorphism and agarose gel electrophoresis. Results: p16 540C→G genotype distribution was found to be: CC: 66.2%, CG: 28.4%, GG: 5.4%; p16 580C→T genotype distribution was found to be: CC: 82.4%, CT: 17.6%, TT: 0% and MDM2 genotype distribution was found to be: TT: 31.1%, TG: 47.3%, GG: 21.6% in patients with prolactinoma. Tumor diameter before treatment was correlated with prolactin levels before treatment and percentage of prolactin decrease with treatment (r=0.719, p<0.001, p=0.034 r=0.256, respectively). The number of patients with tumor size decrease of more than 50% in those with homozygous genotype (TT+GG) of MDM2 SNP309T→G was significantly higher than in heterozygous genotype (TG) carriers (odds ratio(OR)=0.18, 95% confidence interval(CI)=0.06-0.58; p=0.003). Conclusion: This study showed that p16 and MDM2 polymorphisms do not play a decisive role in tumorigenesis, but some genotypes of these polymorphisms might be associated with follow-up characteristics of prolactinoma.

2014-03-15, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, BAĞ SOYTAŞ, RABİA, TURGUT, SEDA, BÜYÜKKABA, MİTAT, TAŞAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TURGUT, SEDA, TAŞAN, ERTUĞRUL